Singapore Proposes Mandatory Pre-Market Notification for Health Supplements

Singapore's Health Sciences Authority (HSA) has initiated a public consultation on a proposed regulatory framework for Complementary Health Products (CHPs), which encompasses health supplements, traditional medicines, homeopathic medicines, medicated oils, balms, plasters, and topical antiseptics. This move aims to transition the current voluntary product notification system, introduced in 2022, to a mandatory pre-market notification requirement for all health supplements available in Singapore.

Currently, health supplements in Singapore do not require pre-market approval. However, the HSA's new proposal mandates product listing for CHPs, requiring adherence to specific safety, quality, labelling, record-keeping, safety reporting, and advertising standards. Products failing to undergo this mandatory notification will be blocked from market entry. Furthermore, information on all notified products will become publicly accessible via the HSA's website.

This regulatory shift reflects a drive towards enhanced consumer protection and market transparency. The definition of CHPs generally covers self-care products with a long history of safe use, intended for general health support or relief of minor, self-manageable conditions. As of 30 June 2026, only 664 products have been voluntarily notified under the existing scheme, indicating a significant portion of market entrants may not have engaged with the current framework.

What this means for Singapore

Brand owners and manufacturers operating in Singapore must prepare for substantial changes in market access. The introduction of mandatory pre-market notification will necessitate a rigorous update of product dossiers to comply with HSA's new safety, quality, and labelling requirements. Non-compliance after the framework's implementation will result in market exclusion. Companies with existing voluntary notifications must reassess their submissions against the stricter mandatory criteria, potentially incurring reformulation or re-registration costs. This new framework presents an opportunity for compliant brands to enhance consumer trust through publicly validated product information, potentially gaining a competitive edge over smaller, less compliant operators who may struggle with the increased regulatory burden and documentation overhead by early 2027.

Separately, the United Natural Products Alliance (UNPA) will cease operations at the end of 2026 following the retirement of its founder and president, Loren Israelsen. Established in 1992, UNPA played a crucial role in shaping the 1994 Dietary Supplement Health and Education Act (DSHEA) in the United States, providing a regulatory and policy backbone that facilitated the growth of the US supplement industry. Israelsen highlighted that the industry now boasts numerous capable trade associations, making UNPA's continued operation redundant in his view. This closure, while significant for its historical contribution to US regulation, has minimal direct impact on the Singaporean market, primarily affecting US industry advocacy and representation.

Also presented at the 19th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health (IPC) in Krakow, Christian Roghi, co-founder of Microbiome Futures, discussed the critical role of biotics research for astronaut health during extended space missions. NASA's objective to send astronauts to Mars by 2030 underscores the urgency of finding solutions for biological challenges over a potential 24-month mission. While this research is primarily focused on space exploration and under-served populations, it foreshadows potential long-term insights and ingredient innovations for the probiotics sector, likely impacting product development and claims in the distant future. This research is currently in its early stages and does not present immediate commercial implications for supplement manufacturers.

For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.